BioCentury | Feb 13, 2021
Management Tracks

New venture partners at SR One; plus moves at Surface Oncology, Agenus, AbCellera, BioDelivery, Transcenta, Dewpoint, Cortexyme, Cerevance and Penrose

...as the venture arm of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), SR One was spun out last year.Surface Oncology Inc. (NASDAQ:SURF...
...GenScript in September. No formal change has been made against Zhang, the company said. BC Staff SR One Surface Oncology Inc. Agenus...
BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...COVID-19. " title="Interactive or visual content" frameborder="0" scrolling="no" style="width:100%;height:900px;"> Selina Koch AstraZeneca plc Arcus Biosciences Bristol-Myers Squibb Co. I-Mab Biopharma Akeso Biopharma Surface Oncology Inc. Novartis...
BioCentury | Dec 18, 2020
Product Development

Next-generation checkpoints acting on NK and T cells: Data Byte

...types against tumors. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced Thursday that it licensed an anti-PVRIG mAb from Surface Oncology...
BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

...Senior Editor GlaxoSmithKline’s $85 million deal with Surface Oncology...
...pharma pipelines. On Thursday, the partners announced that Surface Oncology Inc....
...cell immunoglobulin and mucin domain 3 Lauren Martz GlaxoSmithKline plc Surface Oncology Inc....
BioCentury | Oct 13, 2020
Product Development

Oct. 13 Quick Takes: J&J pauses dosing in COVID-19 vaccine trials; plus Voyager, Avenue and Surface Oncology

...The company’s shares lost $6.51 (59%) to $4.53 on Monday.Surface Oncology lifts on M&A reportImmuno-oncology company Surface Oncology Inc....
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...He is a strategic adviser at Third Rock Ventures and chairs bluebird bio Inc. (NASDAQ:BLUE), Surface Oncology Inc....
BioCentury | May 21, 2020
Product Development

May 20 Quick Takes: Filgotinib meets in ulcerative colitis; broader labels for Lynparza, Tecentriq, plus updates from Eiger, eGenesis and more

...see “French VC Sofinnova Expanding Start-up Ecosystem in Italy” ). Surface Oncology gains on Merck deal Surface Oncology Inc....
...focus on gastric cancers that have developed resistance to checkpoint inhibition. The stock move brings Surface Oncology’s...
...sch 066336) SRF617 Keytruda, pembrolizumab (MK-3475, lambrolizumab) Gilead Sciences Inc. Galapagos N.V. Merck & Co. Inc. Eiger BioPharmaceuticals Inc. eGenesis Inc. ICB International Sofinnova Partners Surface Oncology Inc. San...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

...they all look very different.” Jeff Goater, Surface Oncology However, early clinical studies, in particular by Surface Oncology Inc....
...further dose escalation/expansion.” A separate Phase I trial in combination with Rituxan rituximab is ongoing. Surface Oncology Inc....
...China Novimmune S.A., Plan-les-Ouates, Switzerland OSE Immunotherapeutics S.A. (Euronext:OSE), Nantes, France Stanford University, Stanford, Calif. Surface Oncology Inc....
BioCentury | May 24, 2019
Preclinical News

May 24 Preclinical Quick Takes: Baker-Garcia team controls cytokine receptor signaling; plus data from Surface, Innate, Moderna and Lyvgen

...different phases of red blood cell development. Surface, Innate show preclinical efficacy for immunometabolism mAbs Surface Oncology Inc....
...EpoR - Erythropoietin receptor Sandi Wong, Staff Writer IPH52, IPH5201 IPH53 LVGN6051 MRNA-1944 SRF373 (NZV930) SRF617 Innate Pharma S.A. Lyvgen Biopharma Co. Ltd. Moderna Inc. Stanford University Surface Oncology Inc. University...
BioCentury | May 11, 2019
Translation in Brief

Arvinas, Palleon founders extend the reach of targeted degraders

...extracellular lipoprotein APOE4, which plays a role in neurodegenerative diseases, as well as the cell surface oncology...
Items per page:
1 - 10 of 36
BioCentury | Feb 13, 2021
Management Tracks

New venture partners at SR One; plus moves at Surface Oncology, Agenus, AbCellera, BioDelivery, Transcenta, Dewpoint, Cortexyme, Cerevance and Penrose

...as the venture arm of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), SR One was spun out last year.Surface Oncology Inc. (NASDAQ:SURF...
...GenScript in September. No formal change has been made against Zhang, the company said. BC Staff SR One Surface Oncology Inc. Agenus...
BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...COVID-19. " title="Interactive or visual content" frameborder="0" scrolling="no" style="width:100%;height:900px;"> Selina Koch AstraZeneca plc Arcus Biosciences Bristol-Myers Squibb Co. I-Mab Biopharma Akeso Biopharma Surface Oncology Inc. Novartis...
BioCentury | Dec 18, 2020
Product Development

Next-generation checkpoints acting on NK and T cells: Data Byte

...types against tumors. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced Thursday that it licensed an anti-PVRIG mAb from Surface Oncology...
BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

...Senior Editor GlaxoSmithKline’s $85 million deal with Surface Oncology...
...pharma pipelines. On Thursday, the partners announced that Surface Oncology Inc....
...cell immunoglobulin and mucin domain 3 Lauren Martz GlaxoSmithKline plc Surface Oncology Inc....
BioCentury | Oct 13, 2020
Product Development

Oct. 13 Quick Takes: J&J pauses dosing in COVID-19 vaccine trials; plus Voyager, Avenue and Surface Oncology

...The company’s shares lost $6.51 (59%) to $4.53 on Monday.Surface Oncology lifts on M&A reportImmuno-oncology company Surface Oncology Inc....
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...He is a strategic adviser at Third Rock Ventures and chairs bluebird bio Inc. (NASDAQ:BLUE), Surface Oncology Inc....
BioCentury | May 21, 2020
Product Development

May 20 Quick Takes: Filgotinib meets in ulcerative colitis; broader labels for Lynparza, Tecentriq, plus updates from Eiger, eGenesis and more

...see “French VC Sofinnova Expanding Start-up Ecosystem in Italy” ). Surface Oncology gains on Merck deal Surface Oncology Inc....
...focus on gastric cancers that have developed resistance to checkpoint inhibition. The stock move brings Surface Oncology’s...
...sch 066336) SRF617 Keytruda, pembrolizumab (MK-3475, lambrolizumab) Gilead Sciences Inc. Galapagos N.V. Merck & Co. Inc. Eiger BioPharmaceuticals Inc. eGenesis Inc. ICB International Sofinnova Partners Surface Oncology Inc. San...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

...they all look very different.” Jeff Goater, Surface Oncology However, early clinical studies, in particular by Surface Oncology Inc....
...further dose escalation/expansion.” A separate Phase I trial in combination with Rituxan rituximab is ongoing. Surface Oncology Inc....
...China Novimmune S.A., Plan-les-Ouates, Switzerland OSE Immunotherapeutics S.A. (Euronext:OSE), Nantes, France Stanford University, Stanford, Calif. Surface Oncology Inc....
BioCentury | May 24, 2019
Preclinical News

May 24 Preclinical Quick Takes: Baker-Garcia team controls cytokine receptor signaling; plus data from Surface, Innate, Moderna and Lyvgen

...different phases of red blood cell development. Surface, Innate show preclinical efficacy for immunometabolism mAbs Surface Oncology Inc....
...EpoR - Erythropoietin receptor Sandi Wong, Staff Writer IPH52, IPH5201 IPH53 LVGN6051 MRNA-1944 SRF373 (NZV930) SRF617 Innate Pharma S.A. Lyvgen Biopharma Co. Ltd. Moderna Inc. Stanford University Surface Oncology Inc. University...
BioCentury | May 11, 2019
Translation in Brief

Arvinas, Palleon founders extend the reach of targeted degraders

...extracellular lipoprotein APOE4, which plays a role in neurodegenerative diseases, as well as the cell surface oncology...
Items per page:
1 - 10 of 36